Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: Trends in the hospital and community settings

Journal of Infection in Developing Countries

Volumn 3, Issue 4, 2009, Pages 295-299

  Khanfar, Husam S ^a,b   Bindayna, Khalid M ^b   Senok, Abiola C ^c   Botta, Giuseppe A ^d  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

^c UNIVERSITY OF SHARJAH   (United Arab Emirates)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

Antibiotic resistance; Escherichia coli; Extended spectrum beta lactamase; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACITRACIN; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; COMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; OUTPATIENT; PHENOTYPE; PREVALENCE; RISK FACTOR; SAUDI ARABIA; SENESCENCE; TREND STUDY; URINALYSIS;

ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SAUDI ARABIA; YOUNG ADULT;

EID: 67649484680     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.127     Document Type: Article

References (21)

1. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S (1983) Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11: 315-317.
2. Bradford PA (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14: 933-951.
3. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18: 657-686.
4. El-Khizzi NA, Bakheshwain SM. (2006) Prevalence of extended-spectrum beta-lactamases among Enterobacteriaceae isolated from blood culture in a tertiary care hospital. Saudi Med J 27: 37-40.
5. Kader AA, Angamuthu K (2005) Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other Gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J 26: 956-959.
6. Kader AA, Kumar AK (2004) Prevalence of extended spectrum beta-lactamase among multidrug resistant Gram-negative isolates from a general hospital in Saudi Arabia. Saudi Med J 25: 570-574.
7. Panhotra BR, Saxena AK, Al-Ghamdi AM (2004) Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. Saudi Med J 25:1871-1876.
8. Babay HA (2002) Detection of extended-spectrum β-lactamases in members of the family enterobacteriaceae at a teaching hospital, Riyadh, Kingdom of Saudi Arabia. Saudi Med J 23: 186-190.
9. Mokaddas EM, Abdulla AA, Shati S and Rotimi VO (2008). The technical aspects and clinical significace of detecting extended-spectrum beta-lactamase-producing enterobacteriaceae at a tertiary-care hospital in Kuwait. J Chemother; 20:445-451.
10. Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D (2008) Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. Med Princ Pract 17: 32-36.
11. Centers for Disease Control National Nosocomial Study Site Definition Manual (1999) Center for Disease Control Atlanta GA.
12. Performance standards for antimicrobial susceptibility testing; 15th informational supplement (M100-S15) (2005) National Committee for Clinical Laboratory Standards, Wayne, Pa, USA, National Committee for Clinical Laboratory Standards.
13. Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN (1999) In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis; 35: 307-315.
14. Ishikawa K, Hayakawa S, Miyakawa S, Kusaka M, Shiroki R, Hoshinaga K (2005) Survey of the susceptibility of urinary isolates to antibacterial agents in 2003. J Infect Chemother 11: 44-47
15. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, Woodford N (2007) CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:165-174.
16. Kader AA, Kumar A, Kamath KA. (2007) Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 28:1114-1116.
17. Lartigue M-F, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P (2007) Ertapenem Resistance of Escherichia coli. Emerg Infect Dis 132.
18. Paterson DL (2006). Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 34: S20-28.
19. Peterson LR (2008) Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-1actamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect Suppl 1: 181-184
20. Mehrgan H, Rahbar M (2008) Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrob Agents 31:147-151.
21. Sorlozano A, Gutierrez J, Romero JM, de Dios LJ, Damas M, Piedrola G (2007) Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 47:413-416.